Element Biosciences closed a Series E funding round exceeding $175 million. The company will use the capital to advance its sequencing technology and expand commercial operations. The round underscores investor confidence in the firm's genomic analysis platform.
Tap to vote and see what everyone thinks.
Summary by ByteBrief
City Therapeutics Raises $99.5M in Series B Funding